<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04374994</url>
  </required_header>
  <id_info>
    <org_study_id>0105643</org_study_id>
    <nct_id>NCT04374994</nct_id>
  </id_info>
  <brief_title>Daily Avanafil for Erectile Dysfunction</brief_title>
  <official_title>Evaluation of the Clinical and Molecular Efficacy of Daily Avanafil in Egyptian Males With Erectile and Endothelial Dysfunction (Randomized Placebo-Controlled Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alexandria</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alexandria</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the investigators tried to study the effect of daily avanafil on the serum
      level of endothelial function markers, nitric oxide (NO), cyclic guanosine monophosphate
      (cGMP) and endothelin-1 (ET1) as well as its impact on the erectile function in males with
      erectile and endothelial dysfunction by comparing the results with controls who received
      placebo. The results revealed improvement in the serum levels of the markers and erectile
      function in avanafil treated group versus placebo after 4 week treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Avanafil is a highly selective and potent oral phosphodiesterase type 5 inhibitor (PDE5-I) .
      However, its impact on the soluble markers of endothelial function has not been investigated
      yet. This study was conducted to assess the effect of daily avanafil on the erectile function
      and endothelial markers' serum level. In this work we recruited 70 males with erectile
      dysfunction and other diseases commonly associated with endothelial dysfunction like diabetes
      mellitus (DM), hypertension (HTN) and dyslipidemia. The investigators randomly treated 70
      patients with 50mg daily oral avanafil and the other 70 patients with placebo. The
      investigators measured the International Index of Erectile Function -5 score (IIEF- 5) and
      the serum levels of endothelin-1 (ET1), nitric oxide (NO) and cyclic guanosine monophosphate
      (cGMP) as markers of endothelial function at baseline and after four weeks treatment. At the
      end of study, the participants randomized to avanafil achieved statistically significant
      improvement in erectile function, endothelin-1, nitric oxide and cyclic guanosine
      monophosphate levels from baseline versus placebo regardless the type and duration of
      associated comorbidity, the duration and severity of erectile dysfunction. These results
      permitted the investigators to conclude that daily avanafil is effective in treatment of
      patients with erectile dysfunction and impaired endothelial function.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2018</start_date>
  <completion_date type="Actual">October 10, 2019</completion_date>
  <primary_completion_date type="Actual">April 15, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage of change of NO serum level from baseline to 4 weeks</measure>
    <time_frame>After 4 weeks treatment</time_frame>
    <description>To calculate the percentage of change of Nitric oxide (NO)(in µmol/L) serum level from baseline to 4 weeks post-treatment with avanafil</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of change of cGMP serum level from baseline to 4 weeks</measure>
    <time_frame>After 4 weeks treatment</time_frame>
    <description>To calculate the percentage of change of cyclic guanosine monophosphate (cGMP) (in pmol/ml) serum level from baseline to 4 weeks post-treatment with avanafil</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of change of ET1 serum level from baseline to 4 weeks</measure>
    <time_frame>After 4 weeks treatment</time_frame>
    <description>To calculate the percentage of change of endothelin-1 (ET1) (in ng/L) serum level from baseline to 4 weeks post-treatment with avanafil</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparing avanafil with placebo group regarding post-treatment NO serum levels and percentage of change from baseline.</measure>
    <time_frame>After 4 weeks treatment</time_frame>
    <description>To compare avanafil with placebo group regarding post-treatment nitric oxide (NO) (in µmol/L) serum level and percentage of change from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparing avanafil with placebo group regarding post-treatment cGMP serum levels and percentage of change from baseline.</measure>
    <time_frame>After 4 weeks treatment</time_frame>
    <description>To compare avanafil with placebo group regarding posttreatment cyclic guanosine monophosphate (cGMP) (in pmol/ml) serum level and percentage of change from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparing avanafil with placebo group regarding post-treatment ET1 serum levels and percentage of change from baseline.</measure>
    <time_frame>After 4 weeks treatment</time_frame>
    <description>To compare avanafil with placebo group regarding post-treatment endothelin-1 (ET1) (in ng/L) serum level and percentage of change from baseline.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Measuring the degree of improvement in the IIEF-5 score</measure>
    <time_frame>After 4 weeks treatment</time_frame>
    <description>The ED male's clinical response to daily avanafil was subjectively assessed by measuring the degree of improvement in the International Index of Erectile Function scoring (IIEF-5 ) score</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>intervention group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Males with sexual dysfunction who received daily avanafil tablets (50mg) for four weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Males with sexual dysfunction who received daily placebo tablets for four weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avanafil 50 MG</intervention_name>
    <description>Oral phosphodiesterase type 5 inhibitors</description>
    <arm_group_label>intervention group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>lactose 25%, maize starch 5%, magnesium stearate 1%, and microcrystalline cellulose 69%, Egypt</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men with clinical diagnosis of erectile dysfunction of any severity.

          -  Should be associated with systemic disorders indicative of endothelial dysfunction
             such as diabetes mellitus , dyslipidemia and/or hypertension

        Exclusion Criteria:

          -  Erectile dysfunction due to psychogenic causes, hypogonadism, or spinal cord injury.

          -  Leukemia and

          -  Multiple myeloma

          -  nitrates or anticoagulants intake.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abdelaal Elkamshoushi, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Alexandria</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty of Medicine, Alexandria University.</name>
      <address>
        <city>Alexandria</city>
        <state>Elazareta</state>
        <zip>21500</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Konstantinopoulos A, Giannitsas K, Athanasopoulos A, Spathas D, Perimenis P. The impact of daily sildenafil on levels of soluble molecular markers of endothelial function in plasma in patients with erectile dysfunction. Expert Opin Pharmacother. 2009 Feb;10(2):155-60. doi: 10.1517/14656560802678211 .</citation>
    <PMID>19236190</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 27, 2020</study_first_submitted>
  <study_first_submitted_qc>May 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2020</study_first_posted>
  <last_update_submitted>May 6, 2020</last_update_submitted>
  <last_update_submitted_qc>May 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alexandria</investigator_affiliation>
    <investigator_full_name>Shimaa Ismail Abdelhamid</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>erectile dysfunction</keyword>
  <keyword>endothelial dysfunction</keyword>
  <keyword>Avanafil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Because we will publish the study in a journal</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 20, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/94/NCT04374994/Prot_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 20, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/94/NCT04374994/SAP_003.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

